Literature DB >> 16794569

Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene.

Gavin Bart1, K Steven LaForge, Lisa Borg, Charles Lilly, Ann Ho, Mary Jeanne Kreek.   

Abstract

The mu opioid receptor is centrally involved in the development of the addictive diseases. It also modulates the stress responsive hypothalamic-pituitary-adrenal axis. Receptors encoded by the variant 118G polymorphism in exon 1 of the mu opioid receptor gene have a threefold increase in beta-endorphin binding and beta-endorphin is three times more potent in receptor-mediated activation of G protein-coupled inwardly rectifying potassium channels. Humans with this variant have increased stress response following opioid antagonism. Here, we study basal levels of adrenocorticotropic hormone and cortisol in subjects with this variant. In all, 59 healthy adults were genotyped and had morning levels of adrenocorticotropic hormone and cortisol measured following intravenous administration of saline placebo. Subjects with a 118G allele had significantly greater levels of cortisol than subjects with the prototype gene. Groups did not differ in levels of adrenocorticotropic hormone. A planned comparison revealed significantly greater cortisol in females with at least one copy of the 118G allele compared to females with the prototype gene. There was no significant effect of gender alone, nor was there a significant interaction between gender and genotype, on ACTH or cortisol. Subjects with at least one copy of the 118G allele have increased basal levels of cortisol, which may influence the susceptibility to and treatment of the stress responsive dyscrasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794569     DOI: 10.1038/sj.npp.1301128

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  24 in total

1.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Role of a functional human gene polymorphism in stress responsivity and addictions.

Authors:  M J Kreek
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

Review 4.  Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment.

Authors:  Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2011-08       Impact factor: 5.691

Review 5.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 6.  Genetics of opiate addiction.

Authors:  Brian Reed; Eduardo R Butelman; Vadim Yuferov; Matthew Randesi; Mary Jeanne Kreek
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

7.  μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer.

Authors:  Andrey V Bortsov; Robert C Millikan; Inna Belfer; Richard L Boortz-Marx; Harendra Arora; Samuel A McLean
Journal:  Anesthesiology       Date:  2012-04       Impact factor: 7.892

8.  Assessment of opioid receptor μ1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia.

Authors:  Özlem Solak; Müjgan Özdemir Erdoğan; Handan Yıldız; Alper Murat Ulaşlı; Fatima Yaman; Evrim Suna Arıkan Terzi; Sena Ulu; Ümit Dündar; Mustafa Solak
Journal:  Rheumatol Int       Date:  2014-03-27       Impact factor: 2.631

9.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

Review 10.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.